Laurent Ducry serves as Vice President, Biologics Development and Manufacturing. In this role, Dr. Ducry is responsible for the Kodiak Group’s biologic drug substance and drug product manufacturing, including the oversight and supervision of Kodiak’s contract manufacturing suppliers and global supply chain. Dr. Ducry joins Kodiak after a successful 19-year career at Lonza where he led the bioconjugate business of Lonza including the large scale commercial supply of marketed antibody-drug conjugate products. Prior to leading the bioconjugate commercial team, Dr. Ducry was Group Leader Bioconjugates R&D with a focus on the development and scale-up of bioconjugation processes. He was previously Senior Scientist, developing chemical processes and producing pharmaceutical intermediates and APIs under cGMP. Dr. Ducry studied chemistry and obtained his Ph.D. from the ETH Zürich (Switzerland). He held a Swiss National Science Foundation postdoctoral fellowship at the University of Pennsylvania in Philadelphia with Prof. A. B. Smith, III and Prof. R. Hirschmann.
Vice President, Biologics Development and Manufacturing